Close Menu

NEW YORK – The European Commission has granted conditional marketing authorization to Blueprint Medicines' avapritinib (Ayvakyt) for the treatment of unresectable or metastatic gastrointestinal stromal tumors with a PDGFRA D842V mutation.

The EC based its decision on the results of the Phase I NAVIGATOR trial, in which the overall response rate in 38 patients was 95 percent on avapritinib, with 13 percent experiencing a complete response. Median progression-free survival was 24 months and overall survival was not reached.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.